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WAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:ith incre ing geographic spread, frequ ncy, and magnitude of outbreaks, dengue contin-
ues to pose a major public health threat worldwide. Dengvaxia, a dengue live-attenuated tet-
ravalent vaccine, was licensed in 2015, but post hoc analyses of long-term data showed
serostatus-dependent vaccine performance with an excess risk of hospitalized and severe
dengue in seronegative vaccine recipients. The World Health Organization (WHO) recom-
mended that only persons with evidence of past dengue infection should receive the vac-
cine. A test for pre-vaccination screening for dengue serostatus is needed. To develop the
target product profile (TPP) for a dengue pre-vaccination screening test, face-to-face con-
sultative meetings were organized with follow-up regional consultations. A technical working
group was formed to develop consensus on a reference test against which candidate pre-
vaccination screening tests could be compared. The group also reviewed current diagnostic
landscape and the need to accelerate the evaluation, regulatory approval, and policy devel-
opment of tests that can identify seropositive individuals and maximize public health impact
of vaccination while avoiding the risk of hospitalization in dengue-naive individuals. Pre-vac-
cination screening strategies will benefit from rapid diagnostic tests (RDTs) that are afford-
able, sensitive, and specific and can be used at the point of care (POC). The TPP described
the minimum and ideal characteristics of a dengue pre-vaccination screening RDT with an
emphasis on high specificity. The group also made suggestions for accelerating access to
these RDTs through streamlining regulatory approval and policy development. Risk and
benefit based on what can be achieved with RDTs meeting minimal and optimal characteris-
tics in the TPP across a range of seroprevalences were defined. The final choice of RDTs in
each country will depend on the performance of the RDT, dengue seroprevalence in the tar-
get population, tolerance of risk, and cost-effectiveness.
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Author summary
This paper describes the consensus on the minimum and ideal performance and opera-
tional characteristics of rapid tests that would be used for dengue pre-vaccination screen-
ing. This profile will incentivize industry to develop better pre-vaccination screening tests.
The choice of which test to use depends on the seroprevalence of the population targeted
for vaccination and the optimal balance between benefit and risks. The group also made
suggestions for accelerating access to these pre-vaccination screening tests through
streamlining regulatory approval and policy development.
Introduction
Dengue is a major public health problem with more than 3.6 billion people at risk for dengue
virus (DENV) infection and an estimated 390 million infections annually in over 120 tropical
and subtropical countries [1,2]. With increasing geographic spread, frequency, and magnitude
of outbreaks, dengue has also become a major problem in international travelers [3,4]. In the
absence of truly effective and sustainable vector control measures, a dengue vaccine is urgently
needed. The first dengue vaccine was licensed in 2015: the live-attenuated recombinant tetra-
valent vaccine CYD-TDV (DAU : PleasenotethatPLOSdoesnotallowtrademarksðor1ÞorcopyrightsymbolsðÞinthemanuscript:engvaxia) d veloped by San fi Pasteur. However, post hoc analy-
ses of the long-term data in the multicountry Phase III trials showed serostatus-dependent
vaccine performance of Dengvaxia. An excess risk of hospitalized and severe dengue was
found in year 3 after vaccination in baseline seronegative vaccine recipients, while in seroposi-
tive vaccine recipients, the vaccine was efficacious and safe [5]. The World Health Organiza-
tion (WHO) recommended that only persons with evidence of a past DENV infection
(seropositive) should receive the vaccine; hence, pre-vaccination screening for dengue serosta-
tus is needed [6]. To support the strategy, WHO and other expert panels highlighted the urgent
need for rapid diagnostic tests (RDTs) to determine serostatus. Pre-vaccination screening
strategies will benefit from RDTs that are affordable, sensitive, and specific and can be used at
the point of care (POC) in a population-wide program [6]. To date, no RDT has been licensed
for the indication of determining dengue serostatus.
In this paper, we discuss the processes that led to the final target product profile (TPP) for a
dengue RDT for pre-vaccination screening, development of RDTs in comparison to dengue
ELISA testing, current RDT landscape and hurdles for marketing new RDTs, and consider-
ations in RDTs performance to maximize public health impact.
The processes toward TPP development
To develop the TPP for a dengue pre-vaccination screening RDT, face-to-face consultative
meetings were organized by the Partnership for Dengue Control and the Global Dengue and
Aedes-transmitted Diseases Consortium (GDAC) with follow-up regional consultations. The
first face-to-face consultative meeting was in January 2019. Prior to the meeting, a preliminary
draft of the TPPs was prepared based on online consultations and discussions with key
regional experts. During the 2019 meeting, the preliminary draft was presented for further
refinement through focus groups and individual discussions. Semi-structured interviews were
also conducted with 16 different experts and country representatives from Latin America and
Asia Pacific regions. A draft TPP was published as part of the 2019 meeting report [7]. A sec-
ond face-to-face meeting was organized in January 2020. During this follow-up meeting, 10
more key informant interviews were conducted with country representatives and key opinion
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leaders. The International Diagnostics Centre (IDC) at the London School of Hygiene and
Tropical Medicine (LSHTM) was mandated to lead the next steps toward finalizing the TPP. A
technical working group was formed with the responsibility of developing consensus on a ref-
erence test against which candidate dengue pre-vaccination screening RDTs could be
compared.
A meeting of the technical working group was convened online on May 14, 2020, with the
goal of arriving at a consensus on the reference standard for the pre-vaccination screening test
TPP. During the meeting, data were presented from comprehensive analyses of baseline sam-
ples from over 3,800 participants in the immunogenicity subsets of the CYD-TDV vaccine
Phase III trials (CYD14 and CYD15). The updates provided the rationale and evidence sup-
porting the selection of an appropriate reference standard.
The reference standard and final TPP
To arrive at a reference standard, a comprehensive analysis of the advantages and disadvan-
tages of different potential reference tests was performed based on data from the Phase III clin-
ical trial of the CYD14 and CYD15 immunogenicity subset [8,9].
Plaque Reduction Neutralization Test 90 (PRNT90) is the most specific DENV serological
test and is recommended by WAU : PleasenotethatasperPLOSstyle; donotusethewordtheinfrontofWHO;CIRM; oracronymsthatarepronouncedasaword:HO for det rmining past dengue exposure in ndemic ar as
[10]. However, neutralizing antibodies are only a small subset of antibodies produced in
response to infection. Hence if PRNT is used as a reference standard alone, there will be false-
negative pre-vaccination screening results that lead to people with prior dengue infection being
denied vaccination. Therefore, some modifications should be made to minimize this potential
bias. The nonstructural protein 1 (NAU : PleasenotethatNS1hasbeendefinedasnonstructuralprotein1inthesentenceThenonstructuralprotein1ðNS1ÞimmunoglobulinGðIgGÞELISA::::Pleasecheckandcorrectifnecessary:S1) immunoglobulin G (IAU : PleasenotethatIgGhasbeendef edasimmunoglobulinGinthesentenceThenonstructuralprotein1ðNS1Þimmunoglobu inGðIgGÞELISA::::Pleasecheckandcorrectifnecessary:gG) ELISA a Plaque Reduction
Neutralization Test 50 (PAU : PleasenotethatPRNT50hasbeendefinedasPlaqueReductionNeutralizationTest50inthesentenceThenonstructuralprotein1ðNS1ÞimmunoglobulinGðIgGÞELISA::::Pleasecheckandcorrectifnecessary:RNT50) c n be used to minimize this bias. The deng NS1 IgG ELISA
assay offers excellent discrimination of previous dengue infection and shows no evidence of
cross-reactivity with Japanese encephalitis and yellow fever, while results from a very limited
number of post-Zika virus (ZIKV) and West Nile virus samples were inconclusive [11].
The technical working group considered the use of PRNT90, PRNT50, and dengue NS1 IgG
ELISA as a reference dengue serostatus algorithm in Fig 1 [12].
The advantage of the above algorithm is that it may provide the most accurate representa-
tion of true dengue serostatus. However, the disadvantages are that PRNT requires specialized
Fig 1. Algorithm for using PRNT90, PRNT50, and dengue NS1 IgG ELISA for reference dengue serostatus
determination [12]. IAU : AbbreviationlistshavebeencompiledforthoseusedthroughoutFigs1and2andTable1:Pleaseverifythatallentriesarecorrect:gG, immunoglobu n G; EU/ml, ELISA Units per milliliter; NS1, non tructural protein 1;
PRNT50, Plaque Reduction Neutralization Test 50; PRNT90, Plaque Reduction Neutralization Test 90.
https://doi.org/10.1371/journal.pntd.0009557.g001
PLOS NEGLECTED TROPICAL DISEASES Dengue prevaccination screening test
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009557 July 29, 2021 3 / 10
laboratory setting with assay experience. It is time consuming, requires relatively large serum
volumes, and throughput is limited. Interlaboratory variability in PRNT assay methods may
impact results. DAU : PleasecheckwhethertheeditstothesentenceDengueNS1IgGELISAisyet:::arecorrect; andprovidecorrectwordingifnecessary:engue NS1 IgG ELISA is yet to be set up outside of res arch development
sites.
The technical working group also considered selecting commercially available DENV IgG
ELISAs that have performance characteristics close to this composite reference standard, but
are widely available and can be performed in most laboratories. Sanofi Pasteur has published
data showing that the Panbio Indirect and Euroimmun IgG ELISAs have the best performance
profiles against the PRNT90, PRNT50, and NSI IgG as a serostatus reference standard [13]. The
Euroimmun IgG ELISA exhibits a lower overall cross-reactivity to other flaviviruses, while the
PanBio exhibits moderate levels of cross-reactivity to ZIKV and West Nile virus. This limits
the use of the Panbio Indirect ELISA in areas with high ZIKV prevalence and a moderate sen-
sitivity in detection of DENV serotype 4 monotypic immunes (56%). However, it was sug-
gested that epidemiologically, as ZIKV emerged in dengue endemic areas, transmitted by the
same vector, the prevalence of ZIKV seropositivity generally coincides with that of DENV; in
other words, the prevalence of individuals positive to ZIKV and naive to DENV is probably
very low.
Sanofi Pasteur further evaluated the performance of 3 IgG RDTs using PRNT90, the Panbio
IgG, or the Euroimmun IgG ELISA as comparators, using baseline sera from 6 to 16 year olds
in the CYD14/CYD15 immunosubsets. The results show that the PRNT90 as a comparator
exhibits advantages over 2 commercial IgG ELISAs. Performance estimates for RDTs over a
spectrum of sensitivities show that PRNT90 as comparator yields estimates that are closest to
those with the comparator algorithm shown above. The IgG ELISAs overestimate sensitivity
and underestimate specificity. These differences are accentuated for the high sensitivity IgG
RDTs.
The technical working group concluded that, given the importance of using a test of high
specificity for pre-vaccination screening, PRNT90 should remain as the comparator for the
evaluation of pre-vaccination screening test. This is now shown in the final TPP (Table 1). The
group also recommend that a reference panel be made available for the evaluation of pre-vacci-
nation RDTs as PRNT assays are not widely available worldwide. Furthermore, the group rec-
ommend the development of an external quality assessment (EQA) program for pre-
vaccination screening IgG RDTs and to check lot-to-lot variations.
Current landscape of rapid diagnostic tests
WHO has called for the development of POC tests with adequate performance characteristics
to identify prior DENV infection, i.e., high specificity and sensitivity in order to minimize vac-
cine risk and maximize individual and public health benefits. Until tests specifically designed
for that purpose become available, WHO considered the use of IgG ELISAs and IgG-contain-
ing RDTs as temporizing tools depending on the epidemiological setting [6].
RDTs had variable sensitivities (40% to 70%) that were lower than those of the ELISAs
(>/ = 90%). Cross-reactivity to other flaviviruses was low with RDTs (</ = 7%) but was more
significant with ELISAs (up to 51% for West Nile virus and 34% for ZIKV). For each test, sen-
sitivity appeared similar in samples from individuals with recent (<13 months) versus remote
(3 to 4 years) virologically confirmed DENV infections. In general, dengue IgG RDTs were
found to be more specific and less cross-reactive than ELISAs [13].
Some diagnostic developers have made progress in developing RDTs that can potentially be
used for pre-vaccination screening. Sanofi Pasteur has codeveloped a dengue pre-vaccination
screening IgG RDT that prioritizes very high specificity (to minimize the risk of vaccination of
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Table 1. TPP for a dengue test for pre-vaccination screening.
Characteristic Minimal Optimal Comments
Scope
Goal of test RDT for detection of dengue-specific IgG antibodies indicative of previous dengue infection Detection of all 4 serotypes
Target population Individuals eligible for dengue vaccination Vaccine licensed for 9–45 year olds living
in endemic areas
Target user Minimally trained community health worker Could be the same person who is giving
the vaccine




Functioning vaccination program with clear
understanding and ability to communicate the
risks and benefits of vaccination





Specimen type Finger-prick whole blood �100 μl Finger-prick whole blood �25 μl
Specimen handling Maximum 2 handling steps after finger-prick Direct application of whole blood without handling
Time to result 30 minutes 15 minutes
Result interpretation Visual/qualitative Automated reader/semiquantitative grading of strength of
positivity
Price per test �$7.50 USD �$2.50 USD
Biosafety/waste disposal Simple waste biosafety disposal
Assay stability:
transportation
No cold chain No cold chain, withstand transport stress Use of vaccination supply chains may
facilitate transportation of test kits
Assay stability: operating
conditions and shelf life
10–30˚C and 80% relative humidity,
�12-month shelf life
5–40˚C and 95% relative humidity or individually sealed tests with
desiccants to enable humidity-proof packaging, �18-month shelf
life
Internal control Internal process control line visually to indicate
proper functioning
Presence of additional detection lines to identify cocirculating
flavivirus antibodies for flow-type test formats, for example
Future research may demonstrate if other




No connectivity; manual result reporting in
vaccination record
Automated reader with connectivity for transfer of results to
electronic medical records/databases and patient result
notification
Adequate result reporting can also
facilitate repeat testing of negative
individuals
Test performance
Clinical sensitivity �85% �95% Specificity is a higher priority than
sensitivity
Performance shall be determined in
appropriate samples
Dengue seroprevalence will impact the
required specificity of the test
Clinical specificity �95% �98%
Reference standard PRNT90 The PRNT90 assay was selected as the
reference standard as it has the highest
specificity
PPVs and NPVs �90% �95%
Cross-reactivity No cross-reactivity to other flaviviruses
No cross-reactivity to circulating antibodies from other flavivirus vaccinations
No cross-reactivity to endogenous substances and other pathogens
Characterization of
reference samples
Samples from individuals with the following:
- proven past dengue infection
- no known flavivirus exposure and no
evidence of dengue IgG
- proven previous infection with other
flaviviruses
- prior flavivirus vaccination
Samples from a well-characterized cohort including individuals
with the following:virological confirmation of acute dengue
infection with varying time points after resolution of acute
infection
- no known flavivirus exposure and no evidence of dengue IgG
- proven asymptomatic past dengue infection
- previous infection by other flaviviruses with varying time points
after resolution of infection
- previous infection by both dengue and another flavivirus with
varying time points after resolution of infections
- who have received other flavivirus vaccinations
IgG, immunoglobulin G; NPV, negative predictive value; PPV, positive predictive value; PRNT90, Plaque Reduction Neutralization Test 90; RDT, rapid diagnostic test;
TPP, target product profile.
https://doi.org/10.1371/journal.pntd.0009557.t001
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false-positive individuals), minimal to no flavivirus cross-reactivity, and high sensitivity to
ensure detection of a high proportion of true dengue-seropositive individuals [9,13]. At the
2020 meeting, 4 diagnostic companies presented on the status of development of DENV IgG
RDTs. These companies were Bio-Rad, BluSense, Chembio, and CTK Biotech. In general, the
developers reported candidate assays of high specificities with some compromise on their sen-
sitivities. All assays are easy to use with whole blood, serum, and plasma, but each assay has its
own unique advantages and disadvantages. The Chembio assay is a multiplex lateral flow assay
for DENV, ZIKV, and chikungunya, with quantitative detection and data connectivity using a
digital reader. The BluSense immunomagnetic assay has connectivity capabilities and quanti-
tative detection. The CTK Biotech assay is easy to use and has a long shelf life. The Bio-Rad
assay is an easy-to-use lateral flow assay.
Barriers in adoption of new diagnostic tests
Bringing new diagnostic tests to the market may take on average more than 10 years. There are
3 valleys of death that may limit the access of diagnostics. TAU : PleasecheckwhethertheeditstothesentenceTheseincluderegulatory; policy:::arecorrect; andprovidecorrectwordingifnecessary:hese includ regulatory, policy,
financial and health systems barriers. Regulatory barriers can be a major hurdle in ensuring
access to quality-assured diagnostics, as often regulatory science has not kept pace with tech-
nological innovation.
The paradigm of non-inferiority can no longer be used for the regulatory approval of acces-
sible diagnostics. There is an urgent need for joint assessment of risks and benefits by regula-
tors, policy makers, and subject matter experts to accelerate the access pathway. Successes in
implementation of new diagnostics depend on engaging policy makers early in determination
of test performance in settings and populations to maximize individual and public health ben-
efits. Fig 2 illustrates this new regulatory framework that has been proposed as a critical step in
reducing regulatory bottlenecks.
Trade-offs in RDT performance, cost-effectiveness studies, and public
health impact
Pre-vaccination RDTs are designed to identify the population eligible for vaccination. These
tests should have very high specificity to exclude those individuals not eligible for vaccination
(dengue seronegatives) to reduce potential harm by inadvertently vaccinating false-seroposi-
tive individuals. High specificity typically comes at the cost of test sensitivity, and, hence, a loss
in detecting those previously exposed to dengue and who are the most likely to benefit from
vaccination. Different modeling approaches show that in settings with high endemicity
Fig 2. Proposed new regulatory policy framework to accelerate regulatory approval for IVD. IVD, in vitro
diagnostics.
https://doi.org/10.1371/journal.pntd.0009557.g002
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(prevalence >70%), this trade-off will result in little net change in vaccination impact com-
pared to vaccination without prior screening. However, in settings with lower dengue trans-
mission, the screen and vaccinate strategy would improve the impact of vaccination versus a
no testing strategy. Positive predictive values (PPVs) and negative predictive values (NPVs),
which combine positive and negative pretest probability and performance characteristics of a
given test, have been proposed as alternative and more meaningful cross-setting indicators.
While PPV constrains RDT accuracy in low prevalence settings, NPV constraints do so for
high prevalence settings [14].
To fulfill both criteria, a very sensitive (>85%) and highly specific (>95%) RDT is required.
According to our consensus TPP, a pre-vaccination screening RDT should be used in a sero-
prevalence setting at which its PPV is 90% or greater (Table 1). Countries should decide, based
on their own seroprevalence levels and risk management approach, which levels of test perfor-
mance and predictive values they would adopt. Table 2 presents a series of case scenarios of
dengue seroprevalence ranges covered by tests meeting minimal and optimal criteria for per-
formance (sensitivity and specificity) and predictive values. For instance, a test with 95% sensi-
tivity and 98% specificity covers the 30% to 70% seroprevalence range with 95% PPV and 90%
NPV. PPV and NPV need not be symmetrical, depending on a country’s situation and choices.
For example, a test with 75% sensitivity works just as well as a test with 80% sensitivity for pop-
ulations with seroprevalences between 25% and 30%. However, as shown in Table 2, at a sero-
prevalence of 50%, a test with sensitivities of 75% and 80% will lead to NPVs of 81% and 83%,
respectively. Increasing test sensitivity to 90% will restore the PPV and NPV to acceptable lev-
els, i.e., above 90%.
For settings with seroprevalences less than 16%, it may be useful to consider the use of a test
with 99% specificity or use a 2-test algorithm to increase specificity. In low and moderately
endemic settings, a screen-and-vaccinate strategy would streamline the use of vaccine, reduce
the safety risk of vaccinating individuals without prior exposure to the virus, and drastically
reduce the number of doses used against the additional expenses from testing a whole birth
cohort. Cost-effectiveness is likely most sensitive to the specificity of the test, as a lack thereof
Table 2. Relationship between test performance and its predictive values when screening populations of different seroprevalence.
Dengue seroprevalence Test
performance
Predictive values Distribution of test outcomes among 10,000 people screened Mitigation








15% 75% 98% 87% 96% 1,125 170 8,330 375 Confirm positives
80% 98% 88% 97% 1,200 170 8,330 300
90% 98% 89% 98% 1,350 170 8,330 150
95% 98% 89% 99% 1,425 170 8,330 75
75% 99% 93% 96% 1,125 85 8,415 375
25% 75% 98% 93% 92% 1,875 150 7,350 625
80% 98% 93% 94% 2,000 150 7,350 500
90% 98% 94% 97% 2,250 150 7,350 250
95% 98% 94% 98% 2,375 150 7,350 125
50% 75% 98% 97% 80% 3,750 100 4,900 1,250 Confirm negatives
80% 98% 98% 83% 4,000 100 4,900 1,000
90% 98% 98% 91% 4,500 100 4,900 500
95% 98% 98% 95% 4,750 100 4,900 250
NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity.
https://doi.org/10.1371/journal.pntd.0009557.t002
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will result in additional vaccine costs that are used to generate a net negative health impact
through the vaccination of seronegative individuals. Published models diverge on their predic-
tion of cost-effectiveness of a test and vaccinate strategy, spanning from not cost-effective to
highly cost-effective for endemic countries including the Philippines and Brazil [9,15]. The
assumed case fatality ratios may be a key driver for such differences. At the same time, cost-
effectiveness models tend to underestimate the loss of effectiveness in terms of public health
impact of vaccination campaigns when the test is not sensitive enough and would turn in
false-negative results and miss individuals who would benefit from vaccination and help
reduce transmission.
Modeling studies found that repeat testing could improve return on investment (ROI)
despite increasing intervention costs. Thus, more detailed analyses should address questions
on repeat testing and testing periodicity, in addition to real test sensitivity and specificity
[15,16]. Our results follow from a mathematical model relating ROI to epidemiology, interven-
tion strategy, and costs for testing, vaccination, and dengue infections. The authors applied
this model to a range of strategies, costs and epidemiological settings pertinent to CYD-TDV,
including a range of seroprevalences from 30% to 70% and vaccination both with and without
an RDT (85% sensitivity and 95% specificity). Modeling indicates that it is possible to reduce
hospitalization in the age-eligible cohorts by at least 15% and that from a societal perspective,
it may be at least cost-effective to do so (under incremental cost-effectiveness ratios and ROI).
TAU : PleasecheckwhethertheeditstothesentenceThiscost   effectivenessremainswhenconsidering:::arecorrect; andprovidecorrectwordingifnecessary:his cost-eff ctiveness remains when consid ring multiple testing, and the use of a web-based
app developed at LSHTM proved to aid public health officials in assessing whether an annual
testing program is cost-effective based on the relative cost of the test and vaccine to the cost of
a secondary infection (https://samclifford.shinyapps.io/Denvax_demo/).
Discussion
The current dengue vaccine cannot be deployed without a concurrent prescreening strategy.
While there are now new data on the dengue vaccine and some advancements toward the
development of an RDT that can be used for pre-vaccination screening, current RDTs have
high specificity but at the expense of a lower sensitivity. Future RDTs specifically designed for
dengue pre-vaccination screening are yet to be developed, independently evaluated, undergo
regulatory approval, and registered for use in countries.
In this paper, we provide indications as to what can be achieved with RDTs meeting mini-
mal and optimal characteristics, but the choice of which levels of performance are acceptable
will depend on a country’s appreciation of needs and tolerance of risks.
WHO, in 2019, put in place a Diagnostic Technical Advisory Group (DTAG) to facilitate
the development of new TPPs [17]. In line with the 2021 priorities and with support from part-
ners, the DTAG has already developed TPPs for onchocerciasis, lymphatic filariasis, schistoso-
miasis, soil-transmitted helminthiasis, human African trypanosomiasis, and leprosy. The TPPs
for scabies, yaws, and mycetoma are near completion. Even though the dengue TPP develop-
ment was not captured as a priority of the DTAG for this year, the work described here can
serve as our collective contribution to WHO DTAG process and potentially expedite the evalu-
ation and deployment of a test that is urgently needed for the deployment of dengue vaccines.
The TPP process described in this paper is in line with WHO TPP development process and
will be sent to the DTAG for their review and possible incorporation into WHO Research and
Development (RAU : PleasenotethatRDhasbeendefinedasResearchandDevelopmentinthesentenceTheTPPprocessdescribedinthispaperis::::Pleasecheckandcorrectifnecessary:&D) pathway when appropriate.
In the meantime, the Partnership for Dengue Control and GDAC will continue this work
in collaboration with country partners. The next steps are to develop a mechanism and a pro-
tocol for the independent evaluation of candidate RDTs to be used for dengue pre-vaccination.
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A call for expression of interest to companies will be sent out, and sites in the IDC/LSHTM
biobanking/evaluation network will be approached regarding their interest in participating in
the independent evaluation. Most of these sites were part of WHO/TDR dengue and European
Union–funded ZikaPLAN evaluation networks and are familiar with what needs to be done
and have template agreements that they can sign with companies [18,19]. To accelerate access
to pre-vaccination screening RDTs, IDC will work with regulators and policy makers to
streamline the regulatory approval and policy development for these dengue screening tests
through joint data review and assessment of acceptable risks for the incremental benefits of the
vaccine for the population. This process will be initiated in parallel with the independent eval-
uations of the tests.
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